Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to UIN 114047 on Prescription Drugs: Cost Effectiveness answered on 4 March 2026, if he will provide a copy of the a) impact assessment and b) details of modelling for changes to the National Institute for Health and Care Excellence cost-effectiveness threshold to the Health and Social Care Select Committee.

There are no plans to provide an impact assessment or details of the modelling in relation to changes to the National Institute for Health and Care Excellence’s cost-effectiveness threshold to the Health and Social Care Select Committee. Information included in the impact assessment is commercially sensitive.

The United Kingdom and United States’ pharmaceutical arrangement is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector.